Studija slučaja
https://doi.org/10.3325/cmj.2021.62.288
Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report
Dragan Primorac
orcid.org/0000-0001-5565-080X
; The Henry C. Lee College of Criminal Justice and Forensic Sciences, University of New Haven, West Haven, CT, USA
Sanda Stojanović Stipić
; Medical School, University of Split, Split, Croatia
Marko Strbad
; Educell Ltd., Trzin, Slovenia
Lenart Girandon
; Educell Ltd., Trzin, Slovenia
Ariana Barlič
; Educell Ltd., Trzin, Slovenia
Ivo Ivić
; Medical School, University of Split, Split, Croatia
Daniela Marasović Krstulović
; Department of Internal Medicine, University Hospital Split, Split, Croatia
Irena Jukić
; Croatian Institute of Transfusion Medicine, Zagreb, Croatia
Beata Halassy
; Center for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Zagreb, Croatia
Ana Hećimović
; Croatian Institute of Transfusion Medicine, Zagreb, Croatia
Vid Matišić
; St. Catherine Specialty Hospital, Zagreb/Zabok, Croatia
Vilim Molnar
; St. Catherine Specialty Hospital, Zagreb/Zabok, Croatia
Sažetak
COVID-19 presentations range from cold-like symptoms
to severe symptoms with the development of acute respiratory distress syndrome (ARDS). We report on a severe
COVID-19 patient who was mechanically ventilated and
who developed ARDS and bacterial infection. Because of
rapid clinical deterioration and the exhaustion of other
treatment options, the family and attending physicians
requested a compassionate use of adult allogeneic bone
marrow-derived mesenchymal stem cells (MSC) in addition to commonly used immunosuppressive, antiviral, and
supportive therapy. The clinical course is discussed thoroughly, with a special emphasis on the safety and effect
of MSC therapy. Compassionate MSC treatment, given in
three rounds, affected ARDS regression. The patient was
discharged from the intensive care unit after 31 days and
from hospital after 49 days in a good general condition.
MSC treatment was not associated with any side effects
and was well tolerated in a three-week period; therefore, it
should be studied in larger trials and considered for compassionate use
Ključne riječi
Hrčak ID:
278142
URI
Datum izdavanja:
24.6.2021.
Posjeta: 408 *